Aclarion, Inc.
ACONNasdaqHealthcare · Services-Medical Laboratories · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | |
|---|---|---|---|---|---|
| Revenue | $75,730 | $45,724 | $75,404 | $60,444 | $60,292 |
| Operating income | −$7.1M | −$5.5M | −$4.9M | −$5.6M | −$3.0M |
| Net income | −$7.2M | −$7.0M | −$4.9M | −$7.1M | −$5.0M |
| Total assets | $13.7M | $2.1M | $2.5M | $2.9M | $1.9M |
| Total liabilities | $837,287 | $1.2M | — | — | — |
| Equity | $12.8M | $970,057 | −$727,995 | $2.2M | −$12.8M |
| EPS (diluted) | $-13.61 | $-7478.90 | $-79782.00 | $-19.61 | $-6.58 |
| Shares out. | 582,371 | 7.2M | 7.9M | 491,345 | 905,685 |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- −9312.5%
- Net margin
- −9551.9%
- Return on equity
- −56.4%
- Return on assets
- −52.9%
- Return on capital (ROCE)
- −54.9%
- Liabilities / assets
- 6.1%
- Debt / equity
- 0.07×
- Book value / share
- $22.04
- Revenue growth (YoY)
- 65.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 4.23safe
- Accruals / assets
- −0.5%clean
- Piotroski F-Score
- 6/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 4 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 31, 2025
- NT 10-Qmissed a reporting deadline ↗Aug 14, 2023
- NT 10-Qmissed a reporting deadline ↗May 16, 2023
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Seg Opportunity Fund, LlcPassive (13G)Mar 25, 2026
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 198,536 | 4.0 | -24.5% |
| Apr 30, 2026 | 262,946 | 1.5 | +33.0% |
| Apr 15, 2026 | 197,719 | 1.5 | +39.0% |
| Mar 31, 2026 | 142,278 | 3.1 | -0.3% |
| Mar 13, 2026 | 142,742 | 1.5 | -14.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Other material eventApr 22, 2026
- Entered a material agreement · Modified shareholder rights · Amended charter or bylaws · Other material eventMar 19, 2026
- Regulation FD disclosureJan 13, 2026
- Entered a material agreementJan 9, 2026
- Entered a material agreementOct 14, 2025
- Entered a material agreement · Director / officer change · Regulation FD disclosureSep 3, 2025
- Shareholder voteJul 21, 2025
- Shareholder vote · Regulation FD disclosureJul 7, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 10-QFORM 10-Q FOR MAR 2026May 13, 2026
- 4May 12, 2026
- 4May 12, 2026
- 4May 11, 2026
- 4May 8, 2026
- DEF 14ANOTICE AND PROXY STATEMENTApr 27, 2026
- 8-KFORM 8-KApr 22, 2026
- PRE 14APRELIMINARY PROXY STATEMENTApr 3, 2026
- SCHEDULE 13GMar 25, 2026
- 8-KFORM 8-KMar 19, 2026
- 8-A12BFORM 8-A12BMar 19, 2026
- 10-KFORM 10-K FOR DEC 2025Mar 18, 2026
- 8-KCURRENT REPORTJan 13, 2026
- 8-KCURRENT REPORTJan 9, 2026
- 424B5PROSPECTUS SUPPLEMENT TO PROSPECTUS DATED 5-5-25Jan 9, 2026